ESMO 2026 - TALENT: Neoadjuvant T-DXd. With Dr. Sara Hurvitz

Dr. Sara Hurvitz reviews TALENT, evaluating neoadjuvant T-DXd in HR-positive, HER2-low early breast cancer, with pCR rates below 10% and exploratory biomarker findings that may inform future patient selection.